UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

41.40 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 10, 2022

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For November 10, 2022 ↗

November 10, 2022

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.

Via Benzinga

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

Recap: UroGen Pharma Q4 Earnings ↗

March 21, 2022

UroGen Pharma (NASDAQ:URGN) reported its Q4 earnings results on Monday, March 21, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors

November 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

November 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers

October 11, 2022

From UroGen Pharma Ltd.

Via Business Wire

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution

September 28, 2022

From UroGen Pharma Ltd.

Via Business Wire

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗

September 19, 2022

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

Via Benzinga

Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session ↗

September 16, 2022

Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.

Via Benzinga

UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors

September 12, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Upcoming 2022 Conferences

September 07, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

August 11, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

July 27, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

79 Biggest Movers From Yesterday ↗

June 08, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 25, 2022

On Wednesday, 215 companies set new 52-week lows.

Via Benzinga

UroGen Pharma to Present at Upcoming Investor Conferences

May 18, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer

May 16, 2022

From UroGen Pharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

May 16, 2022

On Monday, 198 companies reached new 52-week lows.

Via Benzinga

UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting

May 13, 2022

From UroGen Pharma Ltd.

Via Business Wire

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

May 10, 2022

From UroGen Pharma Ltd.

Via Business Wire

Earnings Outlook For UroGen Pharma ↗

May 09, 2022

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that UroGen Pharma...

Via Benzinga

UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

May 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

March 29, 2022

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For May 10, 2022 ↗

May 10, 2022

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

Via Benzinga

UroGen Pharma's Return On Capital Employed Overview ↗

March 22, 2022

According to data from Benzinga Pro, during Q4, UroGen Pharma's (NASDAQ:URGN) reported sales totaled $16.17 million. Despite a 5.82% increase in earnings, the company posted a...

Via Benzinga

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

March 21, 2022

From UroGen Pharma Ltd.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.